Trevi Therapeutics (TRVI) Cash & Equivalents (2018 - 2026)

Trevi Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents changed 0.2% year-over-year to $19.4 million; the TTM figure through Mar 2026 stood at $19.4 million (changed 0.2% YoY), while the FY2025 annual figure was $18.9 million, down 44.53% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $19.4 million, up from $18.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $117.1 million in Q2 2025, with the low at $11.6 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $19.4 million (2025), against an average of $29.9 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 72.12% in 2022, then jumped 803.02% in 2025.
• Trevi Therapeutics' Cash & Equivalents stood at $12.6 million in 2022, then soared by 157.34% to $32.4 million in 2023, then grew by 5.25% to $34.1 million in 2024, then tumbled by 44.53% to $18.9 million in 2025, then grew by 2.63% to $19.4 million in 2026.
• Business Quant data shows TRVI's Cash & Equivalents at $19.4 million in Q1 2026, $18.9 million in Q4 2025, and $56.9 million in Q3 2025.